Selective estrogen receptor modulators promising for cardiac syndrome X
Selective estrogen receptor modulators promising for cardiac syndrome X
复制标题
选择性雌激素受体调节剂有望治疗 X 型心脏综合征
DOI：
10.4103/0022-3859.70936
复制
发表时间：
2010-10-01
影响因子：
1.6
通讯作者：
Wang, J. F.
中科院分区：
文献类型：
--
作者：
Chen, Y. X.;Luo, N. S.;Wang, J. F.
Cardiac syndrome X (CSX) is defined as a typical anginal-like chest pain with a transient ischemic electrocardiogram, but without abnormal coronary angiography. It is usually accepted that endothelial dysfunction, inflammation, oxidative stress and estrogen deficiency are the main reasons of CSX. There are some methods to treat CSX including statins, beta blocker, angiotensin converting enzyme inhibitors, nitrates, estrogen, and so on. The estrogen replacement therapy (ERT), in particular, has been reported by many researchers to significantly reduce the frequency of chest pain after administration of estrogen, which has been explained as estrogen acting on its receptor to improve the endothelial function. However, it has been suggested that ERT must not be used for coronary heart disease due to its adverse effects. However, some selective estrogen receptor modulators (SERMs) can inhibit inflammatory response as well as oxidative stress, and improve the endothelial function, to reduce the occurrence of chest pain. Here, we hypothesize that SERMs may be the beneficial selection for patients with CSX.
